Rick has over 35 years of experience in business management and new business/technology development in the life science industry. He has held executive leadership positions in multinational corporations as well as early-stage ventures. He retired from Millipore in 2010, where he was VP of the Drug Discovery & Development business unit mid 2006 through 2010. Millipore was acquired by Merck KGaA in mid-2010, and Rick supported several aspects of the integration process with EMD and Serono.
Prior to Millipore, Rick was the President of LINCO Research, a company that developed and commercialized diagnostic kits and services for biomedical research. LINCO was a leader in the development of multiplex assays for the Luminex platform. Rick started his career in biotechnology at Monsanto, where he held several Director level roles in technology and business management, including Commercial Development, Strategic Planning and International Markets. Currently, Rick serves as CEO of Apertus Pharmaceuticals, a developer and manufacturer of generic API and finished dose formulations.
Rick received a B.S. in Chemistry (Central College, Pella IA), his PhD in Biochemistry (University of Illinois), a Post Doctoral Fellowship (American Cancer Society – U of Wisconsin) and his executive MBA (Washington University in St. Louis). He is a Distinguished Alumni award recipient from the Olin School of Business at Wash U.